nigericin has been researched along with emodin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, JW; Heo, KH; Jeong, JH; Kang, TB; Kwak, SB; Lee, KH; Shim, DW; Shin, WY; Sim, EJ | 1 |
| Chen, F; Gao, H; Jiang, R; Liu, Y; Liu, Z; Mei, J; Wang, B | 1 |
2 other study(ies) available for nigericin and emodin
| Article | Year |
|---|---|
Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Carrier Proteins; Emodin; Endotoxins; Inflammasomes; Inflammation; Interleukin-1beta; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Nigericin; NLR Family, Pyrin Domain-Containing 3 Protein; Oxygenases; Silicon Dioxide | 2015 |
Emodin relieves the inflammation and pyroptosis of lipopolysaccharide-treated 1321N1 cells by regulating methyltransferase-like 3 -mediated NLR family pyrin domain containing 3 expression.
Topics: Caspase 1; Emodin; Humans; Inflammation; Interleukin-10; Interleukin-6; Lipopolysaccharides; Methyltransferases; Nigericin; NLR Family, Pyrin Domain-Containing 3 Protein; Pyrin Domain; Pyroptosis; Tumor Necrosis Factor-alpha | 2022 |